Tenascins in fibrotic disorders—from bench to bedside

Cell Adhesion and Migration

Volumn 9, Issue 1-2, 2015, Pages 83-89

  Kasprzycka, M ^a   Hammarstrom C ^a   Haraldsen, G ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Biomarker; Extracellular matrix remodeling; Fibrosis; Inflammation; Tenascin

Indexed keywords

ALPHA INTERFERON; FIBRONECTIN; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TENASCIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; CELL DIFFERENTIATION; CELL INTERACTION; CELL MIGRATION; CHRONIC INFLAMMATION; COLLAGEN SYNTHESIS; EHLERS DANLOS SYNDROME; FIBROSIS; GENE MUTATION; HEART MUSCLE FIBROSIS; HUMAN; MOLECULARLY TARGETED THERAPY; MYOFIBROBLAST; MYOPATHY; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; TISSUE REPAIR; ANIMAL; INFLAMMATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; FIBROSIS; HUMANS; INFLAMMATION; MYOFIBROBLASTS; SIGNAL TRANSDUCTION; TENASCIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84943248305     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/19336918.2014.994901     Document Type: Review

References (76)

1. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18:1028-40; http://dx.doi.org/10.1038/nm.2807
2. Chiquet-Ehrismann R, Orend G, Chiquet M, Tucker RP, Midwood KS. Tenascins in stem cell niches. Matrix Biol 2014; 37:112-23
3. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003; 200:488-99; http://dx.doi.org/10.1002/path.1415
4. Chiquet-Ehrismann R, Tucker RP. Tenascins and the importance of adhesion modulation. Cold Spring Harb Perspect Biol 2011; 3; http://dx.doi.org/10.1101/cshperspect.a004960
5. Sato I, Shimada K. Quantitative analysis of tenascin in chordae tendineae of human left ventricular papillary muscle with aging. Ann Anat 2001; 183:443-8; http://dx.doi.org/10.1016/S0940-9602(01)80202-8
6. Geffrotin C, Garrido JJ, Tremet L, Vaiman M. Distinct tissue distribution in pigs of tenascin-X and tenascin-C transcripts. Eur J Biochem 1995; 231:83-92; http://dx.doi.org/10.1111/j.1432-1033.1995.0083f.x
7. Voermans NC, Verrijp K, Eshuis L, Balemans MC, Egging D, Sterrenburg E, van Rooij IA, van der Laak JA, Schalkwijk J, van der Maarel SM, et al. Mild muscular features in tenascin-X knockout mice, a model of Ehlers-danlos syndrome. Connect Tissue Res 2011; 52:422-32; http://dx.doi.org/10.3109/03008207.2010.551616
8. El-Karef A, Yoshida T, Gabazza EC, Nishioka T, Inada H, Sakakura T, Imanaka-Yoshida K. Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J Pathol 2007; 211:86-94; http://dx.doi.org/10.1002/path.2099
9. Zhao Y, Young SL, McIntosh JC. Induction of tenascin in rat lungs undergoing bleomycin-induced pulmonary fibrosis. Am J Physiol 1998; 274:L1049-57
10. Carey WA, Taylor GD, Dean WB, Bristow JD. Tenascin-C deficiency attenuates TGF-ss-mediated fibrosis following murine lung injury. Am J Physiol Lung Cell Mol Physiol 2010; 299:L785-93; http://dx.doi.org/10.1152/ajplung.00385.2009
11. Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 2001; 81:1015-24; http://dx.doi.org/10.1038/labinvest.3780313
12. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 2005; 167:71-80; http://dx.doi.org/10.1016/S0002-9440(10)62954-9
13. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, et al. Tenascin-C is an endogenous activator of Tolllike receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15:774-80; http://dx.doi.org/10.1038/nm.1987
14. Goh FG, Piccinini AM, Krausgruber T, Udalova IA, Midwood KS. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J Immunol 2010; 184:2655-62; http://dx.doi.org/10.4049/jimmunol.0903359
15. Kanayama M, Kurotaki D, Morimoto J, Asano T, Matsui Y, Nakayama Y, Saito Y, Ito K, Kimura C, Iwasaki N, et al. Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J Immunol 2009; 182:8015-25; http://dx.doi.org/10.4049/jimmunol.0900725
16. Clark RA, Erickson HP, Springer TA. Tenascin supports lymphocyte rolling. J Cell Biol 1997; 137:755-65; http://dx.doi.org/10.1083/jcb.137.3.755
17. Nakahara H, Gabazza EC, Fujimoto H, Nishii Y, D’Alessandro-Gabazza CN, Bruno NE, Takagi T, Hayashi T, Maruyama J, Maruyama K, et al. Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse. Eur J Immunol 2006; 36:3334-45; http://dx.doi.org/10.1002/eji.200636271
18. Hemesath TJ, Marton LS, Stefansson K. Inhibition of T cell activation by the extracellular matrix protein tenascin. J Immunol 1994; 152:5199-207
19. Hibino S, Kato K, Kudoh S, Yagita H, Okumura K. Tenascin suppresses CD3-mediated T cell activation. Biochem Biophys Res Commun 1998; 250:119-24; http://dx.doi.org/10.1006/bbrc.1998.9258
20. Hinz B. The myofibroblast: paradigm for a mechanically active cell. J Biomech 2010; 43:146-55; http://dx.doi.org/10.1016/j.jbiomech.2009.09.020
21. Wynn TA. Cellular and molecularmechanisms of fibrosis. J Pathol 2008; 214:199-210; http://dx.doi.org/10.1002/path.2277
22. Trebaul A, Chan EK, Midwood KS. Regulation of fibroblast migration by tenascin-C. Biochem Soc Trans 2007; 35:695-7; http://dx.doi.org/10.1042/BST0350695
23. Kaarteenaho-Wiik R, Paakko P, Sormunen R. Ultrastructural features of lung fibroblast differentiation into myofibroblasts. Ultrastruct Pathol 2009; 33:6-15; http://dx.doi.org/10.1080/01913120802608430
24. Gewin L, Zent R. How does TGF-beta mediate tubulointerstitial fibrosis? Semin Nephrol 2012; 32:228-35; http://dx.doi.org/10.1016/j.semnephrol.2012.04.001
25. Boor P, Sebekova K, Ostendorf T, Floege J. Treatment targets in renal fibrosis. Nephrol Dial Transplant 2007; 22:3391-407; http://dx.doi.org/10.1093/ndt/gfm393
26. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009; 326:1216-9; http://dx.doi.org/10.1126/science.1176009
27. Alcaraz LB, Exposito JY, Chuvin N, Pommier RM, Cluzel C, Martel S, Sentis S, Bartholin L, Lethias C, Valcourt U. Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-beta. J Cell Biol 2014; 205:409-28; http://dx.doi.org/10.1083/jcb.201308031
28. Derynck R, Zhang YE. Smad-dependent and Smadindependent pathways in TGF-beta family signalling. Nature 2003; 425:577-84; http://dx.doi.org/10.1038/nature02006
29. Burch GH, Gong Y, Liu W, Dettman RW, Curry CJ, Smith L, Miller WL, Bristow J. Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. Nat Genet 1997; 17:104-8; http://dx.doi.org/10.1038/ng0997-104
30. Mao JR, Taylor G, Dean WB, Wagner DR, Afzal V, Lotz JC, Rubin EM, Bristow J. Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition. Nat Genet 2002; 30:421-5; http://dx.doi.org/10.1038/ng850
31. Lethias C, Carisey A, Comte J, Cluzel C, Exposito JY. A model of tenascin-X integration within the collagenous network. FEBS Lett 2006; 580:6281-5; http://dx.doi.org/10.1016/j.febslet.2006.10.037
32. Margaron Y, Bostan L, Exposito JY, Malbouyres M, Trunfio-Sfarghiu AM, Berthier Y, Lethias C. Tenascin-X increases the stiffness of collagen gels without affecting fibrillogenesis. Biophys Chem 2010; 147:87-91; http://dx.doi.org/10.1016/j.bpc.2009.12.011
33. Wallace WA, Howie SE, Lamb D, Salter DM. Tenascin immunoreactivity in cryptogenic fibrosing alveolitis. J Pathol 1995; 175:415-20; http://dx.doi.org/10.1002/path.1711750409
34. Kaarteenaho-Wiik R, Tani T, Sormunen R, Soini Y, Virtanen I, Paakko P. Tenascin immunoreactivity as a prognostic marker in usual interstitial pneumonia. Am J Respir Crit Care Med 1996; 154:511-8; http://dx.doi.org/10.1164/ajrccm.154.2.8756830
35. Kaarteenaho-Wiik R, Lakari E, Soini Y, Pollanen R, Kinnula VL, Paakko P. Tenascin expression and distribution in pleural inflammatory and fibrotic diseases. J Histochem Cytochem 2000; 48:1257-68; http://dx.doi.org/10.1177/002215540004800909
36. Fitch PM, Howie SE, Wallace WA. Oxidative damage and TGF-beta differentially induce lung epithelial cell sonic hedgehog and tenascin-C expression: implications for the regulation of lung remodelling in idiopathic interstitial lung disease. Int J Exp Pathol 2011; 92:8-17; http://dx.doi.org/10.1111/j.1365-2613.2010.00743.x
37. Brissett M, Veraldi KL, Pilewski JM, Medsger TA, Jr., Feghali-Bostwick CA. Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3. Arthritis Rheum 2012; 64:272-80; http://dx.doi.org/10.1002/art.30647
38. Kaarteenaho-Wiik R, Mertaniemi P, Sajanti E, Soini Y, Paakko P. Tenascin is increased in epithelial lining fluid in fibrotic lung disorders. Lung 1998; 176:371-80; http://dx.doi.org/10.1007/PL00007619
39. Hisatomi K, Sakamoto N, Mukae H, Hayashi T, Amenomori M, Ishimoto H, Fujita H, Ishii H, Nakayama S, Ishimatsu Y, et al. Elevated levels of tenascin-C in patients with cryptogenic organizing pneumonia. Intern Med 2009; 48:1501-7; http://dx.doi.org/10.2169/internalmedicine.48.2233
40. Fujita H, Sakamoto N, Ishimatsu Y, Kakugawa T, Nakashima S, Hara S, Hara A, Mukae H, Kohno S. Elevated tenascin-C levels in bronchoalveolar lavage fluid of patients with sarcoidosis. Lung 2012; 190:537-43; http://dx.doi.org/10.1007/s00408-012-9400-1
41. Muller S, Neureiter D, Stolte M, Verbeke C, Heuschmann P, Kirchner T, Aigner T. Tenascin: a sensitive and specific diagnostic marker of minimal collagenous colitis. Virchows Arch 2001; 438:435-41; http://dx.doi.org/10.1007/s004280000375
42. Lebensztejn DM, Sobaniec-Lotowska ME, Kaczmarski M, Voelker M, Schuppan D. Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. World J Gastroenterol 2006; 12:3338-43
43. Lieber CS, Weiss DG, Paronetto F. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res 2008; 32:1031-9; http://dx.doi.org/10.1111/j.1530-0277.2008.00664.x
44. Golledge J, Clancy P, Maguire J, Lincz L, Koblar S. The role of tenascin C in cardiovascular disease. Cardiovasc Res 2011; 92:19-28; http://dx.doi.org/10.1093/cvr/cvr183
45. Imanaka-Yoshida K, Aoki H. Tenascin-C and mechanotransduction in the development and diseases of cardiovascular system. Front Physiol 2014; 5:283; http://dx.doi.org/10.3389/fphys.2014.00283
46. Schenke-Layland K, Stock UA, Nsair A, Xie J, Angelis E, Fonseca CG, Larbig R, Mahajan A, Shivkumar K, Fishbein MC, et al. Cardiomyopathy is associated with structural remodelling of heart valve extracellular matrix. Eur Heart J 2009; 30:2254-65; http://dx.doi.org/10.1093/eurheartj/ehp267
47. Kotby AA, Abdel Aziz MM, El Guindy WM, Moneer AN. Can serum tenascin-C be used as a marker of inflammation in patients with dilated cardiomyopathy? Int J Pediatr 2013; 2013:608563; http://dx.doi.org/10.1155/2013/608563
48. Jian B, Jones PL, Li Q, Mohler ER, 3rd, Schoen FJ, Levy RJ. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 2001; 159:321-7; http://dx.doi.org/10.1016/S0002-9440(10)61698-7
49. Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 1996; 179:321-5; http://dx.doi.org/10.1002/(SICI)1096-9896(199607)179:3%3c321::AID-PATH555%3e3.0.CO;2-8
50. Wallner K, Li C, Fishbein MC, Shah PK, Sharifi BG. Arterialization of human vein grafts is associated with tenascin-C expression. J Am Coll Cardiol 1999; 34:871-5; http://dx.doi.org/10.1016/S0735-1097(99)00272-7
51. Kenji K, Hironori U, Hideya Y, Michinori I, Yasuhiko H, Nobuoki K. Tenascin-C is associated with coronary plaque instability in patients with acute coronary syndromes. Circ J 2004; 68:198-203; http://dx.doi.org/10.1253/circj.68.198
52. Pedretti M, Rancic Z, Soltermann A, Herzog BA, Schliemann C, Lachat M, Neri D, Kaufmann PA. Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies. Atherosclerosis 2010; 208:382-9; http://dx.doi.org/10.1016/j.atherosclerosis.2009.07.043
53. Ihida-Stansbury K, McKean DM, Lane KB, Loyd JE, Wheeler LA, Morrell NW, Jones PL. Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 291:L694-702; http://dx.doi.org/10.1152/ajplung.00119.2006
54. Satta J, Soini Y, Pollanen R, Paakko P, Juvonen T. Tenascin expression is associated with a chronic inflammatory process in abdominal aortic aneurysms. J Vasc Surg 1997; 26:670-5; http://dx.doi.org/10.1016/S0741-5214(97)70068-5
55. Paik DC, Fu C, Bhattacharya J, Tilson MD. Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm. Exp Mol Med 2004; 36:524-33; http://dx.doi.org/10.1038/emm.2004.67
56. Horstrup JH, Gehrmann M, Schneider B, Ploger A, Froese P, Schirop T, Kampf D, Frei U, Neumann R, Eckardt KU. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol Dial Transplant 2002; 17:1005-13; http://dx.doi.org/10.1093/ndt/17.6.1005
57. Betz P, Nerlich A, Tubel J, Penning R, Eisenmenger W. Localization of tenascin in human skin wounds–an immunohistochemical study. Int J Legal Med 1993; 105:325-8; http://dx.doi.org/10.1007/BF01222116
58. Latijnhouwers MA, Bergers M, Van Bergen BH, Spruijt KI, Andriessen MP, Schalkwijk J. Tenascin expression during wound healing in human skin. J Pathol 1996; 178:30-5; http://dx.doi.org/10.1002/(SICI)1096-9896(199601)178:1%3c30::AID-PATH442%3e3.0.CO;2-7
59. Dalkowski A, Schuppan D, Orfanos CE, Zouboulis CC. Increased expression of tenascin C by keloids in vivo and in vitro. Br J Dermatol 1999; 141:50-6; http://dx.doi.org/10.1046/j.1365-2133.1999.02920.x
60. Maseruka H, Bonshek RE, Tullo AB. Tenascin-C expression in normal, inflamed, and scarred human corneas. Br J Ophthalmol 1997; 81:677-82; http://dx.doi.org/10.1136/bjo.81.8.677
61. Ljubimov AV, Saghizadeh M, Spirin KS, Khin HL, Lewin SL, Zardi L, Bourdon MA, Kenney MC. Expression of tenascin-C splice variants in normal and bullous keratopathy human corneas. Invest Ophthalmol Vis Sci 1998; 39:1135-42
62. Inoue K, Jinnin M, Hara Y, Makino K, Kajihara I, Makino T, Sakai K, Fukushima S, Inoue Y, Ihn H. Serum levels of tenascin-C in collagen diseases. J Dermatol 2013; 40:715-9; http://dx.doi.org/10.1111/1346-8138.12218
63. Sumioka T, Kitano A, Flanders KC, Okada Y, Yamanaka O, Fujita N, Iwanishi H, Kao WW, Saika S. Impaired cornea wound healing in a tenascin C-deficient mouse model. Lab Invest 2013; 93:207-17; http://dx.doi.org/10.1038/labinvest.2012.157
64. Matsumoto Y, Niimi N, Kohyama K. Characterization of fibrosis-promoting factors and siRNA-mediated therapies in C-protein-induced experimental autoimmune myocarditis. Cell Immunol 2012; 279:70-7; http://dx.doi.org/10.1016/j.cellimm.2012.09.011
65. Nishioka T, Suzuki M, Onishi K, Takakura N, Inada H, Yoshida T, Hiroe M, Imanaka-Yoshida K. Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol 2007; 49:261-8; http://dx.doi.org/10.1097/FJC.0b013e318033dfd4
66. Nishioka T, Onishi K, Shimojo N, Nagano Y, Matsusaka H, Ikeuchi M, Ide T, Tsutsui H, Hiroe M, Yoshida T, et al. Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2010; 298: H1072-8; http://dx.doi.org/10.1152/ajpheart.00255.2009
67. Zou C, Xie R, Bao Y, Liu X, Sui M, M S, Li S, Yin H. Iron chelator alleviates tubulointerstitial fibrosis in diabetic nephropathy rats by inhibiting the expression of tenascinC and other correlation factors. Endocrine 2013; 44:666-74; http://dx.doi.org/10.1007/s12020-013-9907-0
68. Tanaka S, Sumioka T, Fujita N, Kitano A, Okada Y, Yamanaka O, Flanders KC, Miyajima M, Saika S. Suppression of injury-induced epithelial-mesenchymal transition in a mouse lens epithelium lacking tenascin-C. Mol Vis 2010; 16:1194-205
69. Richter HB, Franke H, Dargel R. Expression of tenascin, fibronectin, and laminin in rat liver fibrogenesis–a comparative immunohistochemical study with two models of liver injury. Exp Toxicol Pathol 1998; 50:315-22; http://dx.doi.org/10.1016/S0940-2993(98)80011-0
70. Blaauboer ME, Boeijen FR, Emson CL, Turner SM, Zandieh-Doulabi B, Hanemaaijer R, Smit TH, Stoop R, Everts V. Extracellular matrix proteins: a positive feedback loop in lung fibrosis? Matrix Biol 2014; 34:170-8; http://dx.doi.org/10.1016/j.matbio.2013.11.002
71. Blaauboer ME, Emson CL, Verschuren L, van Erk M, Turner SM, Everts V, Hanemaaijer R, Stoop R. Novel combination of collagen dynamics analysis and transcriptional profiling reveals fibrosis-relevant genes and pathways. Matrix Biol 2013; 32:424-31; http://dx.doi.org/10.1016/j.matbio.2013.04.005
72. Mackie EJ, Halfter W, Liverani D. Induction of tenascin in healing wounds. J Cell Biol 1988; 107:2757-67; http://dx.doi.org/10.1083/jcb.107.6.2757
73. Geffrotin C, Tricaud Y, Crechet F, Castelli M, Lefaix JL, Vaiman M. Unlike tenascin-X, tenascin-C is highly up-regulated in pig cutaneous and underlying muscle tissue developing fibrosis after necrosis induced by very high-dose gamma radiation. Radiat Res 1998; 149:472-81; http://dx.doi.org/10.2307/3579787
74. Assis de Brito TL, Monte-Alto-Costa A, Romana-Souza B. Propranolol impairs the closure of pressure ulcers in mice. Life Sci 2014; 100:138-46; http://dx.doi.org/10.1016/j.lfs.2014.02.007
75. Vorotnikova E, McIntosh D, Dewilde A, Zhang J, Reing JE, Zhang L, Cordero K, Bedelbaeva K, Gourevitch D, Heber-Katz E, et al. Extracellular matrixderived products modulate endothelial and progenitor cell migration and proliferation in vitro and stimulate regenerative healing in vivo. Matrix Biol 2010; 29:690-700; http://dx.doi.org/10.1016/j.matbio.2010.08.007
76. Koyama Y, Kusubata M, Yoshiki A, Hiraiwa N, Ohashi T, Irie S, Kusakabe M. Effect of tenascin-C deficiency on chemically induced dermatitis in the mouse. J Invest Dermatol 1998; 111:930-5; http://dx.doi.org/10.1046/j.1523-1747.1998.00401.x